Cannabidiol (CBD) repurposing as antibacterial: promising therapy of CBD plus polymyxin B against superbugs
N. Abichabki, L. V. Zacharias, N. C. Moreira, F. Bellissimo-Rodrigues, F. d. L. Moreira, J. R. d. L. Benzi, T. M. C. Ogasawara, J. C. Ferreira, L. R. L. Pereira, G. U. L. Braga, C. M. Ribeiro, F. R. Pavan, A. W. Zuardi, J. E. C. Hallak, J. A. d. S. Crippa, V. L. Lanchote, R. Canton, A. L. C. Darini, L. N. Andrade
Abstract
Abstract Multidrug-resistant (MDR) and extensively drug-resistant (XDR) bacteria are a major worldwide public health problem. In the last decades, resistance to last-resort antibiotics such as polymyxin B (PB) have been increasingly observed among these superbugs, compromising the effectiveness of antimicrobial therapy. The present study aimed (i) to assess the ultrapure Cannabidiol (CBD) antibacterial activity against a broad diversity of Gram-negative (GN) and Gram-positive (GP) bacteria (44 different species, 95 strains), comprising standard strains and clinical isolates, and (ii) to investigate the antibacterial activity of the combination CBD + PB against GN bacteria, including chromosomal- and plasmid-acquired PB-resistant and intrinsically PB-resistant GNB. We evaluated CBD in vitro antibacterial activity using the standard broth microdilution method, and the antibacterial activity of the combination CBD + PB was screened using the standard broth microdilution and confirmed by checkerboard assay. CBD exhibited antibacterial activity against different GP bacterial species, lipooligosaccharide (LOS)-expressing GN diplococcus (GND) (Neisseria gonorrhoeae, Neisseria meningitidis, and Moraxella catarrhalis), and Mycobacterium tuberculosis. The combination CBD + PB exhibited antibacterial activity against PB-resistant GNB (e.g., Klebsiella pneumoniae) as well as additive and/or synergistic effect against LOS-expressing GND. The antibacterial activity of the combination CBD + PB against Pseudomonas aeruginosa and plasmid-mediated colistin-resistant (MCR-1) E. coli strains could be only demonstrated in the presence of phenylalanine-arginine-{beta}-naphthylamide (PA{beta}N). In conclusion, our results show promising translational potential of the combination CBD + PB against MDR and XDR GNB, including PB-resistant K. pneumoniae, highlighting its potential as a rescue treatment for life-threatening infections caused by these superbugs. One Sentence SummaryPromising combination of cannabidiol (CBD) + polymyxin B (PB) against superbugs (e.g., PB-resistant Gram-negative bacilli): Repurposing CBD
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Uncovering the hidden antibiotic potential of Cannabis
M. A. Farha, O. M. El-Halfawy, … E. D. Brown·bioRxiv·Jan 15, 2020
- Zidovudine multi-combos with last-line fosfomycin, ceftazidime-avibactam, colistin and tigecycline against Multi-Drug Resistant Klebsiella pneumoniae
M. Gomara-Lomero, A. I. Lopez-Calleja, … S. Ramon-Garcia·bioRxiv·May 17, 2022
- Reversion of antibiotic resistance in drug-resistant bacteria using non-steroidal anti-inflammatory drug benzydamine
- In Vitro Activity of a Novel Metal-Based Antimicrobial against Multidrug-Resistant Klebsiella pneumoniae
Raquel L. Almeida, Nuno Alexandre Faria, … Maria Miragaia·bioRxiv·Mar 1, 2026
- Polyacrylamide-based Antimicrobial Copolymers to Replace or Rescue Antibiotics
Shoshana C. Williams, Madeline B. Chosy, … Eric Andrew Appel·ACS Central SciencePeer-reviewed·Mar 13, 2025
- Assessing the efficacy of therapeutically promising combination of polymyxin B and triclosan against colistin resistant Klebsiella pneumoniae
Soumya Biswas, Pushney Mahapatra, … Mrutyunjay Suar·bioRxiv·Dec 17, 2024